Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatmentbenzinga_article·1 day ago, 12:45 PMMESO-2.06%
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Mondaybenzinga_article·1 day ago, 08:51 AMMESO-2.06%SMTC-12.31%
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back PainUnusual Whales·2 days ago, 07:37 PMMESO-2.06%
Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back painPUBT·2 days ago, 07:35 PMMESO-2.06%
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·Aug 14 at 07:06 AMMESO-2.06%GLOB+2.90%
Stop Falling for Earnings Spin: The True Survivor Game of Biotech, AI Edges, and India ETFsGlobal Report·Aug 11 at 04:43 AMMESO-2.06%TVTX+0.58%
Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?Market Beat·Aug 10 at 12:00 PMMESO-2.06%JPM+0.63%
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy PipelineTip Ranks·Jul 30 at 07:49 AMMESO-2.06%
Mesoblast's Ryoncil® generates $36M in net revenues for the quarter and $115M in the first year of launch.Unusual Whales·Jul 29 at 08:00 PMMESO-2.06%
Australian Stocks Trading Below Fair Value Based On Cash FlowsSimplywall·Jul 27 at 06:16 PMLYSDY-1.88%MESO-2.06%
Why Retail Investors Are Tracking These 3 Founder Led Australian Stocks TodaySimplywall·Jul 25 at 12:07 PMMESO-2.06%
3 Founder Led Stocks With Real Management Alignment Investors May Want To WatchSimplywall·Jul 20 at 04:08 PMMESO-2.06%
Founder Led Stocks For Investors Watching Australian Small Caps CloselySimplywall·Jul 16 at 12:08 AMMESO-2.06%
